Rnaimmune, Inc.

Dong Shen

Patrick Y Lu

Yong-Sik Bong

Shenggao Tang

Ziyang He

Chun Lu

David Brown

Renxiang Chen

Jiaxi He

Neeti Ananthaswamy

Naihsuan C Guy

Ju Hyeong Jeon

Zhifeng Long

Provided herein is a ribonucleic acid (RNA) encoding a spike (S) protein or an immunogenic fragment thereof of a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) comprising at least one non-naturally occurring amino acid mutation. In some embodiments, the S protein is derived from an Omicron variant. Additionally provided are relevant polynucleotides, vectors, cells, compositions, kits, production methods and methods of use.

Composition and methods for MRNA vaccines against novel omicron coronavirus infections

Provided herein is a ribonucleic acid (RNA) encoding a spike (S) protein or an immunogenic fragment thereof of a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) comprising at least one non-naturally occurring amino acid mutation. In some embodiments, the S protein is derived from a delta variant. Additionally provided are relevant polynucleotides, vectors, cells, compositions, kits, production methods and methods of use.

Compositions and methods of mRNA vaccines against novel coronavirus infection

Compositions and methods are provided for potent mRNA vaccines for prevention and treatment of 2019 novel Coronavirus (2019-nCoV) infections. The compositions include a pharmaceutical composition containing one or more mRNA molecules encoding spike protein epitopes, including mutated epitopes, or mRNA cocktails that encode critical viral genes together with pharmaceutically acceptable polymeric nanoparticle carriers and liposomal nanoparticle carriers. Methods for stimulating system immune responses and treatment are provided, including subcutaneous, intraperitoneal and intramuscular injections.

Composition and method of mRNA vaccines against novel coronavirus infection

Growing community of inventors

Baltimore, MD, United States of America

Dong Shen